Biotech Values

[DewDiligence]

Tidbit from today’s MNTA CC: This was the first time Goldman Sachs was represented on a MNTA CC by Jami Rubin, the high-profile analyst who covers Big Pharma. Rubin sounded rather clueless when asking questions about the Copaxone ANDA, but her aggressive stance on the CC might be a prelude to stepped-up coverage of MNTA by GS.